Bli medlem
Bli medlem

Du är här

2015-04-08

Cytokinetics, Inc.: Cytokinetics to Present at the 14th Annual Needham Healthcare Conference

South San Francisco, CA, April 8, 2015 -

Cytokinetics, Incorporated (Nasdaq:CYTK) announced today that Robert I. Blum,
President and Chief Executive Officer, is scheduled to present a corporate
update at the 14thAnnual Needham Healthcare Conference on Wednesday, April
15, 2015 at 11:20 AM at the Westin New York Grand Central in New York, NY.

Interested parties may access the live audio of this presentation by visiting
the Investor Relations section of the Cytokinetics website at
www.cytokinetics.com. The webcast replay of the presentation will be archived
on the Presentations page within the Investor Relations section of
Cytokinetics' website for two weeks following the completion of the event.

About Cytokinetics

Cytokinetics is a clinical-stage biopharmaceutical company focused on the
discovery and development of novel small molecule therapeutics that modulate
muscle function for the potential treatment of serious diseases and medical
conditions. Cytokinetics is developingtirasemtiv
, a fast skeletal muscle activator, as a potential treatment for amyotrophic
lateral sclerosis (ALS).Tirasemtiv
has been granted orphan drug designation and fast track status by the U.S.
Food and Drug Administration and orphan medicinal product designation by the
European Medicines Agency for the potential treatment of ALS. Cytokinetics is
collaborating with Amgen Inc. to developomecamtiv mecarbil
, a cardiac muscle activator, for the potential treatment of heart failure.
Cytokinetics is collaborating with Astellas Pharma Inc. to develop
CK-2127107, a fast skeletal muscle activator, for the potential treatment of
spinal muscular atrophy. Amgen holds an exclusive license worldwide to
develop and commercializeomecamtiv mecarbil
and Astellas holds an exclusive license worldwide to develop and commercialize
CK-2127107. Both licenses are subject to Cytokinetics' specified development
and commercialization participation rights. All of these drug candidates have
arisen from Cytokinetics' muscle biology focused research activities and are
directed towards the cytoskeleton. The cytoskeleton is a complex biological
infrastructure that plays a fundamental role within every human cell.
Additional information about Cytokinetics can be obtained
athttp://www.cytokinetics.com/.

This press release contains forward-looking statements for purposes of the
Private Securities Litigation Reform Act of 1995 (the "Act"). Cytokinetics
disclaims any intent or obligation to update these forward-looking
statements, and claims the protection of the Act's safe harbor for
forward-looking statements. Examples of such statements include, but are not
limited to, statements relating to planned presentations, and the properties
and potential benefits of Cytokinetics' drug candidates and potential drug
candidates. Such statements are based on management's current expectations,
but actual results may differ materially due to various risks and
uncertainties, including, but not limited to, potential difficulties or
delays in the development, testing, regulatory approval and production of
Cytokinetics' drug candidates and potential drug candidates that could slow
or prevent clinical development or product approval, including risks that
current and past results of clinical trials or preclinical studies may not be
indicative of future clinical trials results and that Cytokinetics' drug
candidates and potential drug candidates may have unexpected adverse side
effects or inadequate therapeutic efficacy. For further information regarding
these and other risks related to Cytokinetics' business, investors should
consult Cytokinetics' filings with the Securities and Exchange Commission.

Contacts:
Cytokinetics, Incorporated:

Joanna L. Goldstein
Manager, Investor Relations&Corporate Communications
(650) 624-3000

---------------------------------------

This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Cytokinetics, Inc. via Globenewswire

HUG#1909611

Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.